Drugs and FDA

FDA clears DreaMed’s MODI insulin dosing app for adults with type 2 diabetes

MODI received FDA 510(k) clearance to provide insulin dose recommendations for adults with type 2 diabetes using basal insulin or multiple daily injections.

Reported by 2 outlets Tuesday, September 29, 2026

Hands holding a smartphone
Photo: CC0

The FDA has granted 510(k) clearance to DreaMed Diabetes’ MODI, a mobile app that uses continuous glucose monitoring (CGM) patterns and insulin information to make personalized insulin dose recommendations for adults with type 2 diabetes, Healio reported. MedCity News said MODI is intended for people using basal insulin and those who take multiple daily injections of fast-acting insulin. It must first be prescribed by a physician, according to MedCity News.

According to Healio, the app analyzes users’ glucose patterns and insulin information without requiring a health professional to configure settings or approve recommendations. MedCity News reported users can make adjustments without a provider reviewing each one. Healio said MODI is being assessed in the 13-week, single-arm MODIUS trial, which is enrolling adults with type 1 or type 2 diabetes who require insulin. Its primary outcome is percent time in hypoglycemia with glucose of less than 54 mg/dL.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.